Study 10 of 19Cagrilintide (AM833) literatureThe lancet. Diabetes & endocrinologyTop journal2026
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
Not reported in abstract.
Where it sits
this study against the rest of the cagrilintide (am833) corpus3
Preclinical · this one
3
Observational
0
Open-label
3
Randomised
10
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Cagrilintide (AM833) corpus
AWeight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring, Md.) · 2026 · n=40731 · Coagonists RR=0.43, 95% CI: 0.19 to 0.97reviewABenefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Annals of internal medicine · 2026 · n=112511 · 112,511 participants across 69 studies.reviewAMaximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026 · n=8069 · MD = -13.99 kg vs placebo; 95% CI = -18.38 to -9.61; p < 0.00001reviewBCurrent and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.World journal of clinical pediatrics · 2026 · Semaglutide reduces body mass index by 16.1%.reviewAAmylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026 · n=5425 · -6.08% body weight, -5.89 kg with Cagrilintide monotherapyreviewDBeyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs.Pharmacological research · 2026review